Key features and details
- Rabbit polyclonal to ZNF184
- Suitable for: WB, IP
- Reacts with: Human
- Isotype: IgG
Product nameAnti-ZNF184 antibody
DescriptionRabbit polyclonal to ZNF184
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
- HeLa, Jurkat, 293T whole cell lysates.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: 99% Tris citrate/phosphate
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab176711 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 86 kDa.|
|IP||Use at 2-10 µg/mg of lysate.|
FunctionMay be involved in transcriptional regulation.
Tissue specificityPredominant expression in testis.
Sequence similaritiesBelongs to the krueppel C2H2-type zinc-finger protein family.
Contains 19 C2H2-type zinc fingers.
Contains 1 KRAB domain.
- Information by UniProt
- Zinc finger protein 184 (Kruppel like) antibody
- Zinc finger protein 184 antibody
- ZN184_HUMAN antibody
- ZNF184 antibody
All lanes : Anti-ZNF184 antibody (ab176711) at 0.1 µg/ml
Lane 1 : Jurkat whole cell lysate at 50 µg
Lane 2 : Jurkat whole cell lysate at 15 µg
Lane 3 : HeLa whole cell lysate at 50 µg
Lane 4 : 293T cell whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 86 kDa
Exposure time: 30 seconds
ZNF184 was immunoprecipitated from 1mg Jurkat whole cell lysate using ab176711 at 6 μg/mg lysate (Lane 1), a rabbit anti-ZNF184 antibobody recognizing a downstream epitope (Lane 2) and control IgG (Lane 3). 20% of Immunoprecipitate was loaded per lane and blotted using ab176711 at 1 μg/ml.
Chemiluminescence with exposure times of 10 seconds.
ab176711 has not yet been referenced specifically in any publications.